Breakout Looming?, page-150

I don't have much of an opinion, but there is a lot of negative talk on Hoppers performance v.s. how much hes profited over the years, the best example being the earlier days of IMU. there are others.

The point here is that ALA do not want or need this history to trouble the company, whether justified or not. The business model and niche is very difficult and largely unsuccessful thus high risk, so a lot of this history can come down to this. However the significant profiting from mediocre commercial returns is a concern.

ALA needs patient investors and obviously a bit of luck to get a moonshot treatment through human trials - Its a long road. IMO selling out soon does not make much sense nor will reward early investors or a buyout suitor, who would need to be geared to running the trials. Licensing would make more sense.